A pharmacy attorney explains why boards and plaintiffs now treat USP standards as the baseline, and why research use only labels won't shield sloppy compounding.
Recap by typeshit. Full story at Pharmacy Times.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Bodybuilder Sam Sulek gives his take on peptides in a short clip from Chris Williamson's show. His views are his own, not medical guidance.
Superpower frames apitegromab's FDA approval as a big step and ties it to concern that GLP-1 users can lose a lot of muscle along with fat.
The telehealth company is also adding blood testing services alongside the lower costs for its compounded GLP-1 options.
Inversor Bético rates the business strongly but says entry timing isn't there yet, pointing to margins squeezed by the move from compounded to branded GLP-1s.
Bahrain's National Health Regulatory Authority signed off on the oral GLP-1 version of Wegovy for treating obesity, per the state news agency.
Loading…